The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December 2020 and mathematical models suggest that mRNA vaccines prevented at least 14.4 million deaths from COVID-19 in the first year alone. Their extraordinary effectiveness in having … Read more
Periodontitis, a chronic inflammatory disease of the gums, affects hundreds of millions of people worldwide and is increasingly linked to systemic disorders beyond the oral cavity. Epidemiological studies have long suggested an association between periodontitis and osteoporosis, particularly in postmenopausal women, yet the biological mechanisms connecting these conditions have remained unclear. Growing evidence indicates that … Read more
Known as a Phenotype Analyzer Chip, the diagnostic device can detect minute biological particles in a patient’s bloodstream, providing clues as to how glioblastoma is responding to treatment. It works by testing small samples of blood and identifying messenger cells known as extracellular vesicles that originate from glioblastoma tumour tissue. Developed at the University of … Read more
Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine – which designs nanotechnology-based platforms for clinical translation across specialties – developed a strategy for delivering therapeutic messenger RNA (mRNA) to the inner lining of the uterus (endometrium) in mice via modified lipid nanoparticles (LNPs), which are small capsules made of fatty molecules. … Read more
Weill Cornell Medicine has received a $5.2 million, initial two-year award from the Advanced Research Projects Agency for Health (ARPA-H) Lymphatic Imaging, Genomics, and pHenotyping Technologies (LIGHT) program to develop a comprehensive and innovative approach to diagnosing lymphatic disease. LIGHT is led by ARPA-H Program Manager Kimberley Steele, M.D., Ph.D. The lymphatic system is a network of … Read more
Acute coronary syndrome (ACS) in patients with SARS-CoV-2 infection represents a critical intersection of viral-induced inflammation and cardiovascular pathology. This review explores the dual mechanisms driving SARS-CoV-2-associated ACS and evaluates emerging therapeutic strategies, including phytomedicine and nanotechnology, to address both viral and cardiovascular complications. SARS-CoV-2 and ACS pathogenesis SARS-CoV-2 infection exacerbates ACS through systemic inflammation, … Read more
Newswise — Upconversion Dr. Ho Seong Jang and colleagues at the Extreme Materials Research Center at the Korea Institute of Science and Technology (KIST) have developed an upconversion nanoparticle technology that introduces a core@multi-shell nanostructure, a multilayer structure in which multiple layers of shells surround a central core particle, and enables high color purity RGB … Read more
In a groundbreaking study, a research team from the USA has expanded the potential of carbon capture by showing that multiple abundant materials can effectively pull CO₂ straight from the air. The researchers from Illinois’ Northwestern University introduced new, low-cost materials to facilitate moisture-swing direct air capture (DAC), which traps and releases carbon dioxide depending … Read more
Northeastern professor Mansoor Amiji was elected a 2024 lifetime fellow by the American Association for the Advancement of Science for distinguished achievements over the course of his career. Share this story Copy Link Link Copied! Email Facebook LinkedIn Twitter WhatsApp Reddit Professor of pharmaceutical sciences Mansoor Amiji collaborates with physicians and industry to turn research … Read more
University of Queensland researchers are designing nanotechnology they believe could improve how we treat the most aggressive form of breast cancer. Professor Chengzhong (Michael) Yu and his team are developing novel nanoparticles that could dramatically increase the effectiveness of immunotherapies when treating triple-negative breast cancer (TNBC). TNBC is aggressive, fast-growing and accounts for 30 per … Read more